slide2_res slide3A slide5_res

Info on genetics and psychopathology

This section hosts general information on genetics and psychopathology, articles for parents, families and patients.

Read all articles

Recent Blog posts

The CAPICE blog hosts news and announcements, events, media and articles, mostly written by the Early Stage Researchers (ESRs).

They will pursue the publication of articles about their research during their activities carried on within this project, and this blog will act as a travelogue to disseminate the research results to a broad audience of scientists, clinicians, patients and their parents and the general public.

Read all articles

 

This article contains information of poster "Phenome-wide association study of caffeine PRS and mental health outcomes across the lifespan using the ALSPAC pregnancy cohort " presented by Laura Schellhas, ESR in the CAPICE project, at the 4th Mendelian Randomization Conference in Bristol on July 17, 2019. 

Background: Consumption of caffeinated beverages is widespread, and there is a growing interest in the effects of caffeine on health outcomes. Observationally, caffeine consumption is comorbid with psychiatric symptoms and other substance use (Kendler, Schmitt, Aggen, & Prescott, 2008; Lara, 2010; Treur et al., 2016). Using polygenic risk scores for caffeine consumption as instrumental variables can help to understand the effects of caffeine on such health outcomes, as genetic variants should not be related to common confounding variables, due to random segregation and assortment of alleles (Davey Smith & Ebrahim, 2003). Genome-wide association studies have discovered genetic variants associated with caffeine consumption in the general population (The Coffee and Caffeine Genetics Consortium et al., 2015), but uncertainty remains regarding whether the same genetic variants can be applied to proxy caffeine consumption across the life span and they show pleiotropic associations with comorbid phenotypes.

Aim:  We applied the phenome-wide association study (PheWAS) paradigm to (1) validate the PRS for caffeine consumption for different sources of caffeine (coffee, tea and cola) in four time points in life (offspring: childhood, adolescence; mothers: pregnancy, adulthood) and (2) explore potential pleiotropic effects of the PRS with a variety of mental health phenotypes and substance use behaviours (smoking and alcohol consumption) during these time-points (3) investigate the intergenerational transmission of maternal PRS for caffeine consumption on to offspring.

Method: Data from the Avon Longitudinal Study of Parents and Children (ALSPAC) was used, with available genotype data of 7977 children and 7921 mothers. PRS were derived from 8 genetic variants found to be associated with coffee consumption in the general population (The Coffee and Caffeine Genetics Consortium et al., 2015). In addition to phenotypes for caffeine consumption (total caffeine, caffeine from coffee, tea, and cola in mg/day), mental health, substance use, personality, and sociodemographic phenotypes were included. Overall, 13 phenotypes for children (7-10 years), 47 for adolescents (13-24 years), 49 for pregnant women (measured at 18 and 32 weeks of gestation) and 34 phenotypes for mothers (assessed either before pregnancy or after children reached age 4) were included.

Results: The PRS was found to be positively associated with overall caffeine consumption during 18 (β18w= 5.85, 95% CI18w [3.09, 8.61), p18w = 3.28 e-5) and 32 weeks of pregnancy (β32w = 6.32, 95% CI32w [3.74, 8.89], p32w = 1.56 e-6), as well as caffeine consumed separately through tea (β18w= 2.29, 95% CI18w [0.76, 3.83], p18w = 0.003, β32w= 3.42, 95% CI32w [1.79, 5.03], p32w = 3.65 e-5) and coffee (β18w = 3.67, 95% CI18w [1.20, 6.14], p18w = 0.004, β32w = 3.59, 95% CI32w [1.28, 5.91], p32w = 0.002). For cola, the PRS was negatively associated with consumption at 32 weeks (β32w = -0.20, 95% CI32w [-0.38, -0.03], p32w = 0.02) but not associated at 18 weeks of gestation (β18w = -0.04, 95% CI18w [-0.39, 0.31], 

p18w = 0.83) and not associated with consumption in mothers 97 months after pregnancy (β97m = 0.004, 95% CI97m [-0.002, 0.01], p97m = 0.21). The PRS in offspring predicted neither caffeine consumption in children 8 years of age (β8y = 0.55, 95% CI8y [-0.33, 1.44], p8y = 0.22) nor in adolescents at 13 years of age (β13y = 1.1, 95% CI13y [-0.15, 2.35], p13y = 0.09). After Bonferroni adjustment for multiple testing, neither mothers’ nor offspring’s PRS were found to be associated with our included phenotypes. Lastly, maternal PRS for caffeine was not associated with phenotypes assessed in children under 10 years of age.

Discussion: Overall, our results indicate that PRS for caffeine consumption are valid instruments for assessing actual consumption of tea and coffee, as well as total caffeine consumption in mg/day in adults and pregnant women but not in children. Lack of associations between offspring PRS and caffeine consumption is likely due to low numbers of individuals consuming caffeine in the available age groups (8 and 13 years of age). Contrary to tea and coffee, cola consumption was only found to be associated with PRS for caffeine at 32 weeks of pregnancy with an opposing direction of effect, indicating a false positive finding for this timepoint. Further, our results suggest that the genetic variants used for caffeine consumption are not related to mental health or substance use outcomes.

 

 

 

Project objectives


1. To clarify the role of genetic and environmental factors in the occurrence, course and comorbidity of mental health symptoms across childhood and adolescence..
2. To establish the overlap in genetic risk factors with other characteristics related to childhood mental health symptoms, such as adult mental disorders, IQ and brain structure.
3. To identify genetic (inherited), epigenetic (due to chemical changes to the DNA) and transcriptomic (related to gene expression) variation associated with the occurrence, course and co-morbidity of mental health symptoms during childhood and adolescence.
4. To identify biological pathways associated with mental health symptoms and to validate potential drug targets based on these pathways.
5. To build a prediction model that identifies groups of children that are at highest risk to develop chronic symptoms and that should be targeted for more intensive prevention or treatment programmes.
6. To further develop the already successful EAGLE (EArly Genetics and Lifecourse Epidemiology) consortium into a sustainable international network of researchers in which collaboration is facilitated by data harmonization and IT solutions. This will enable joint analysis of data over cohorts..
7. To build a structure to disseminate the results to a broad audience of scientists, clinicians, patients and their parents and the general public.

These ambitious objectives can be achieved by training of the ESRs in:
- childhood and adolescent mental health symptoms and their (chronic) altereffects (as a result of a non-complete recovery from the mental disorder);
- methods to analyze twin data as well as large-scale (epi)genetic and transcriptomic data across multiple cohorts;
- d
issemination of their results also through this website and its blog.

Get in Touch!

     

Contacts:
Prof. Christel Middeldorp, project coordinator

VU University Amsterdam
Dept. of Biological Psychology
email : c.m.middeldorp(at)vu.nl

Natascha Stroo, project manager
VU University Amsterdam
Dept. of Biological Psychology
email : natascha.stroo(at)vu.nl

Matteo Mauri, web & dissemination manager
University of Cagliari
email : matteo.mauri(at)diee.unica.it

Join our Newsletter

Sign up for our newsletter for all the latest news and information

 
 

Newsletter brought to you by MailChimp.

Project Consortium

Partners